Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Symptoms and General Pathology

Rare Diseases

Lymphoma

Hematologic Neoplasms

Nausea

Vomiting

Signs and Symptoms, Digestive

Lymphosarcoma

Anti-Inflammatory Agents

Antineoplastic Agents

Antiemetics

Gastrointestinal Agents

All Drugs and Chemicals

Anti-Infective Agents

Dexamethasone

Fosaprepitant

Aprepitant

Dexamethasone acetate

BB 1101

Tropisetron

Dexamethasone 21-phosphate

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

HIV Protease Inhibitors

Protease Inhibitors

Enzyme Inhibitors

Neurokinin-1 Receptor Antagonists

Substance P

Neurokinin A

Neurotransmitter Agents

Serotonin

Serotonin 5-HT3 Receptor Antagonists

Tropisetron 5mg（Day1-6）+ Dexamethasone 10mg（Day1-6）+ Aprepitant125mg（Day1-2）、80mg（Day3-6）

Tropisetron 5mg（Day1-6）+ Dexamethasone 10mg（Day1-6）

Tropisetron Hydrochloride Injection 5mg (Day 1-6)

Dexamethasone Sodium Phosphate Injection 10mg (Day 1-6)

Aprepitant 125mg （Day1-2）, 80mg (Day 3-6)

Jun Zhu, MD

The purpose of this study is to evaluate the efficacy and safety of additional aprepitant to standard antiemetic regimen in Autologous Hematopoietic Stem Cell Transplantation.

Chemotherapy-induced nausea and vomiting (CINV) is a serious complication of treatments of hematological malignancies. Although aprepitant has been shown to control CINV in highly emetogenic therapies for solid tumors, the antiemetic effect of aprepitant in hematological chemotherapies is still not clear. In this multi-central perspective randomized controlled study, the investigators are trying to evaluate the efficacy and safety of additional aprepitant to standard antiemetic regimen in Autologous Hematopoietic Stem Cell Transplantation.

A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation

A Multi-central Perspective Randomized Controlled Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation

Time to initial neutrophil engraftment is defined as 1st of 3 consecutive days of an ANC ≥0.5 × 10\^9/L

Time to initial platelet recovery is defined as 1st of 3 consecutive platelet count measurements tested on different days with a count ≥20 × 10\^9/L with no platelet transfusion in the prior 7 days.

Jun Zhu

Department of Hematology Oncology, clinical oncology college, Director of department, Party Secretary

Digestive System Diseases

Liver Neoplasms

Chlorotrianisene

acupoint electric stimulation combined with tropisetron 6mg before TACE

acupoint electric stimulation

tropisetron

Xiaoyan Zhu, Dotral

Xiaoyan Zhu, doc

Xiaoyan Zhu, Doc

Observation on acupoint electric stimulation combined with tropisetron in preventing and treating nausea and vomiting and improving the patient's appetite after TACE for primary or metastatic liver cancer patients.

* Classification of nausea and vomiting, as measured by NCI CTC-AE version 3
* The improvement of appetite, as measure by the classification of Appetite in accordance with NCI CTC-AE version 3.
* Quality of life: use M. D. Anderson symptom scale (the m. d. Anderson Symptom Inventory,MDASI)

Acupoint Electric Stimulation Combined With Tropisetron in Preventing and Treating Nausea and Vomiting After TACE

Fudan University

Attending doctor

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Mouth and Tooth Diseases

Ear, Nose, and Throat Diseases

Uterine Cervical Neoplasms

Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

Carcinoma

Uterine Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Cervical Diseases

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Pharyngeal Neoplasms

Otorhinolaryngologic Neoplasms

Head and Neck Neoplasms

Nasopharyngeal Diseases

Pharyngeal Diseases

Stomatognathic Diseases

Otorhinolaryngologic Diseases

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Cisplatin

Intravenous fosaprepitant of 150mg was given before cisplatin administration on day 1. All patients received tropisetron 5mg and dexamethasone 5mg infusion on day 1 and oral dexamethasone 3.75 mg once a day on day 2-3.

The control group was delivered tropisetron 5mg and dexamethasone 5mg only.

In fosaprepitant group, patients would receive fosaprepitant combined with tropisetron plus dexamethasone to prevent chemoradiotherapy-induced nausea and vomitting while the control group would only be given tropisetron and dexamethasone .

All patients received tropisetron 5mg on day 1.

.All patients received dexamethasone 5mg infusion on day 1 and oral dexamethasone 3.75 mg once a day on day 2-3.

Chuangzhen Chen

The study is to evaluate the antiemetic effect of adding fosaprepitant to biplet regimen of tropisetron and dexamethasone for patients with cervical cancer or nasopharyngeal cancer treated with radiotherapy and concomitant weekly cisplatin chemotherapy in a south Chinese cohort.

The study was designed as a prospective,randomized, single-blind control clinical trial aiming to assess the efficacy and safety of fosaprepitant combined with tropisetron and dexamethasone in preventing nausea and vomiting during 5 weeks of fractionated radiotherapy and concomitant weekly low-dose cisplatin chemotherapy in patients with cervical cancer or nasopharyngeal cancer.

Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer

Fosaprepitant Combined With Tropisetron Plus Dexamethasone in Preventing Nausea and Emesis During Fractionated Radiotherapy With Weekly Cisplatin Chemotherapy in Cervical Cancer and Nasopharyngeal Cancer

The primary endpoint of the study was the cumulative incidence of emesis overall phase (from 1st day of cycle 1 to 7th day of cycle 5, 7 days for one cycle).

Shantou University Medical College

Skin and Connective Tissue Diseases

Breast Neoplasms

Antirheumatic Agents

Central Nervous System Depressants

Psychotropic Drugs

Cyclophosphamide

Olanzapine

Antipsychotic Agents

Selective Serotonin Reuptake Inhibitors

Olanzapine in combination with fosaprepitant and tropisetron

Olanzapine in combination with fosaprepitant, tropisetron and dexamethasone

fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. tropisetron 5mg i.v. on day 1 before undergoing chemotherapy. olanzapine 5mg p.o. on day 1-4

Fosaprepitant , Tropisetron and Olanzapine

On first day, dexamethasone (12 mg) is given orally/intravenously within 30 minutes before cisplatin administrated, and on day 2-4, the given dose of dexamethasone is 8 mg.

fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. tropisetron 5mg i.v. on day 1 before undergoing chemotherapy. olanzapine 5mg p.o. on day 1-4

Fosaprepitant , Tropisetron, Dexamethasone and Olanzapine

Zhenzhen Liu

Standard antiemetic therapy without dexamethasone for the prevention of nausea and vomiting in patients with breast cancer

This is a multicenter, randomized, controlled, open-label, phase III study assessing the efficacy and safety of fosaprepitant, tropisetron and olanzapine for the Prevention of Nausea and Vomiting in Patients With Breast Cancer Receiving Anthracycline/Cyclophosphamide-containing Chemotherapy. Eligible patients will be randomized to receive either standard antiemetic therapy (fosaprepitant, tropisetron, dexamethasone and olanzapine) or standard antiemetic therapy without dexamethasone in a 1:1 ratio.

Fosaprepitant , Tropisetron and Olanzapine for the Prevention of Nausea and Vomiting in Patients With Breast Cancer

Fosaprepitant , Tropisetron and Olanzapine for the Prevention of Nausea and Vomiting in Patients With Breast Cancer Receiving Anthracycline/Cyclophosphamide-containing Chemotherapy

Complete response is defined as a condition in which a patient does not show vomiting or retching and does not require additional treatment with antiemetics. Retching is defined as the physical reaction that accompanies vomiting in the absence of gastric content ejection.

Complete control is defined as a condition where a patient shows no nausea or mild nausea

Total control is defined as a condition where a patient neither shows nausea nor vomiting.

No (or minimal) Impact on patient's Daily Life (NIDL) is generally considered a score ≥54 (6 points mean for each item)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation	NCT02576327	Vomiting	Tropisetron Dexamethasone Aprepitant	18 Years - 65 Years	Peking University
Acupoint Electric Stimulation Combined With Tropisetron in Preventing and Treating Nausea and Vomiting After TACE	NCT01895010	Nausea Vomiting Metastatic Live...	acupoint electr... tropisetron	18 Years -	Fudan University
Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer	NCT05564286	Cervical Cancer Nasopharyngeal ... Chemotherapy-in... Radiation-Induc... Antiemetic	Fosaprepitant tropisetron Dexamethasone	18 Years - 75 Years	Shantou University Medical College
Fosaprepitant , Tropisetron and Olanzapine for the Prevention of Nausea and Vomiting in Patients With Breast Cancer	NCT05242874	Chemotherapy-in...	Fosaprepitant ,... Fosaprepitant ,...	18 Years - 70 Years	Henan Cancer Hospital
Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer	NCT05564286	Cervical Cancer Nasopharyngeal ... Chemotherapy-in... Radiation-Induc... Antiemetic	Fosaprepitant tropisetron Dexamethasone	18 Years - 75 Years	Shantou University Medical College

Spots Global Cancer Trial Database for tropisetron

Every month we try and update this database with for tropisetron cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for tropisetron

Every month we try and update this database with for tropisetron cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for tropisetron cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.